Download PDF
Schlaf 2014; 03(03): 149-155
DOI: 10.1055/s-0038-1626105
Review
Schattauer GmbH

Medikamentöse Behandlung des Restless-Legs-Syndroms

Peter Young
1   Klinik für Schlafmedizin und Neuromuskuläre Erkrankungen, Münster, Email: Peter.Young@ukmuenster.de
› Author Affiliations
Further Information

Publication History

Publication Date:
12 February 2018 (online)

    Permissions and Reprints

Bei der Therapie des Restless-Legs-Syndroms (RLS) sollte man sich immer an der subjektiven Besserung der RLS-Symptome, der Schlafstörung und auch der Lebensqualität orientieren. Neben der geeigneten Wahl des Präparates und supportiven Therapien, wie Eisensupplementierung, sollten RLS-Patienten regelmäßig klinisch untersucht werden, auch um die medikamentöse Therapie nötigenfalls anzupassen und wichtige Differenzialdiagnosen rechtzeitig zu erkennen.

 

  • Literatur

  • 1 Kushida C, Martin M, Nikam P. et al. Burden of restless legs syndrome on health-related quality of life. Qual Life Res 2007; 16: 617-624.
    CrossrefPubMedGoogle Scholar
  • 2 Kushida CA. Clinical presentation, diagnosis, and quality of life issues in restless legs syndrome. Am J Med 2007; 120: S4-S12.
    PubMedGoogle Scholar
  • 3 Hogl B, Kiechl S, Willeit J. et al. Restless legs syndrome: a community-based study of prevalence, severity, and risk factors. Neurology 2005; 64: 1920-1924.
    CrossrefPubMedGoogle Scholar
  • 4 Allen RP, Bharmal M, Calloway M. Prevalence and disease burden of primary restless legs syndrome: results of a general population survey in the United States. Mov Disord 2011; 26: 114-120.
    CrossrefPubMedGoogle Scholar
  • 5 Gamaldo CE, Benbrook AR, Allen RP. et al. Childhood and adult factors associated with restless legs syndrome (RLS) diagnosis. Sleep Med 2007; 8: 716-722.
    CrossrefPubMedGoogle Scholar
  • 6 Silva GE, Goodwin JL, Vana KD. et al. Restless Legs Syndrome, Sleep, and Quality of Life among Adolescents and Young Adults. J Clin Sleep Med 2014; 10: 779-786.
    PubMedGoogle Scholar
  • 7 Allen RP, Picchietti D, Hening WA. et al. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 2003; 4: 101-119.
    CrossrefPubMedGoogle Scholar
  • 8 Hening WA, Allen RP, Washburn M. et al. The four diagnostic criteria for Restless Legs Syndrome are unable to exclude confounding conditions („mimics“). Sleep Med 2009; 10: 976-981.
    CrossrefPubMedGoogle Scholar
  • 9 Walters AS, LeBrocq C, Dhar A. et al. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med 2003; 4: 121-132.
    CrossrefPubMedGoogle Scholar
  • 10 Allen RP, Earley CJ. Augmentation of the restless legs syndrome with carbidopa/levodopa. Sleep 1996; 19: 205-213.
    CrossrefPubMedGoogle Scholar
  • 11 Allen RP, Ondo WG, Ball E. et al. Restless legs syndrome (RLS) augmentation associated with dopamine agonist and levodopa usage in a community sample. Sleep Med 2011; 12: 431-439.
    CrossrefPubMedGoogle Scholar
  • 12 Frauscher B, Gschliesser V, Brandauer E. et al. The severity range of restless legs syndrome (RLS) and augmentation in a prospective patient cohort: association with ferritin levels. Sleep Med 2009; 10: 611-615.
    CrossrefPubMedGoogle Scholar
  • 13 Garcia-Borreguero D, Williams AM. Dopaminergic augmentation of restless legs syndrome: the scope of the problem. Sleep Med 2011; 12: 425-426.
    CrossrefPubMedGoogle Scholar
  • 14 Ondo WG. Common comorbidities and differential diagnosis of restless legs syndrome. J Clin Psychiatry 2014; 75: e06.
    CrossrefPubMedGoogle Scholar
  • 15 Boentert M, Dziewas R, Heidbreder A. et al. Fatigue, reduced sleep quality and restless legs syndrome in Charcot-Marie-Tooth disease: a web-based survey. J Neurol 2010; 257: 646-652.
    CrossrefPubMedGoogle Scholar
  • 16 Shah RS, Rajabally YA. Restless legs syndrome in sensory axonal neuropathy: A case-control study. Rev Neurol (Paris) 2013; 169: 228-233.
    CrossrefPubMedGoogle Scholar
  • 17 Gemignani F, Brindani F. Restless legs syndrome associated with peripheral neuropathy. Eur J Neurol 2007; 14: e9-e10
    Google Scholar
  • 18 Manconi M, Govoni V, De Vito A. et al. Restless legs syndrome and pregnancy. Neurology 2004; 63: 1065-1069.
    CrossrefPubMedGoogle Scholar
  • 19 Trenkwalder C, Hening WA, Montagna P. et al. Treatment of restless legs syndrome: an evidence-based review and implications for clinical practice. Mov Disord 2008; 23: 2267-2302.
    CrossrefPubMedGoogle Scholar
  • 20 Winter AC, Schurks M, Glynn RJ. et al. Restless legs syndrome and risk of incident cardiovascular disease in women and men: prospective cohort study. BMJ Open 2012; 2: e000866
    CrossrefPubMedGoogle Scholar
  • 21 Winter AC, Schurks M, Glynn RJ. et al. Vascular risk factors, cardiovascular disease, and restless legs syndrome in women. Am J Med 2013; 126: 220-227 227 e221–222.
    CrossrefPubMedGoogle Scholar
  • 22 Akpinar S. Restless legs syndrome treatment with dopaminergic drugs. Clin Neuropharmacol 1987; 10: 69-79.
    CrossrefPubMedGoogle Scholar
  • 23 Comella CL. Restless legs syndrome: treatment with dopaminergic agents. Neurology 2002; 58: S87-92.
    CrossrefPubMedGoogle Scholar
  • 24 Hogl B, Paulus W, Clarenbach P. et al. Restless legs syndrome: diagnostic assessment and the advantages and risks of dopaminergic treatment. J Neurol 2006; 253 (Suppl. 04) IV22-28.
    PubMedGoogle Scholar
  • 25 Littner MR, Kushida C, Anderson WM. et al. Practice parameters for the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder. Sleep 2004; 27: 557-559.
    CrossrefPubMedGoogle Scholar
  • 26 Maestri M, Fulda S, Ferini-Strambi L. et al. Polysomnographic record and successful management of augmentation in restless legs syndrome/Willis-Ekbom disease. Sleep Med 2014; 15: 570-575.
    CrossrefPubMedGoogle Scholar
  • 27 Hornyak M, Scholz H, Kohnen R. et al. What treatment works best for restless legs syndrome? Meta-analyses of dopaminergic and non-dopaminergic medications. Sleep Med Rev 2014; 18: 153-164.
    CrossrefPubMedGoogle Scholar
  • 28 Brodeur C, Montplaisir J, Godbout R. et al. Treatment of restless legs syndrome and periodic movements during sleep with L-dopa: a double-blind, controlled study. Neurology 1988; 38: 1845-1848.
    CrossrefPubMedGoogle Scholar
  • 29 Sandyk R, Bernick C, Lee SM. et al. L-dopa in uremic patients with the restless legs syndrome. Int J Neurosci 1987; 35: 233-235.
    CrossrefPubMedGoogle Scholar
  • 30 England SJ, Picchietti DL, Couvadelli BV. et al. L-Dopa improves Restless Legs Syndrome and periodic limb movements in sleep but not Attention-Deficit-Hyperactivity Disorder in a double-blind trial in children. Sleep Med 2011; 12: 471-477.
    CrossrefPubMedGoogle Scholar
  • 31 Garcia-Borreguero D, Larrosa O, Granizo JJ. et al. Circadian variation in neuroendocrine response to L-dopa in patients with restless legs syndrome. Sleep 2004; 27: 669-673.
    PubMedGoogle Scholar
  • 32 Winlow W. Pramipexole in restless legs syndrome: an evidence-based review of its effectiveness on clinical outcomes. Core Evid 2005; 1: 35-42.
    PubMedGoogle Scholar
  • 33 Winkelman JW, Sethi KD, Kushida CA. et al. Efficacy and safety of pramipexole in restless legs syndrome. Neurology 2006; 67: 1034-1039.
    CrossrefPubMedGoogle Scholar
  • 34 Winkelman JW, Johnston L. Augmentation and tolerance with long-term pramipexole treatment of restless legs syndrome (RLS). Sleep Med 2004; 5: 9-14.
    CrossrefPubMedGoogle Scholar
  • 35 Allen R, Becker PM, Bogan R. et al. Ropinirole decreases periodic leg movements and improves sleep parameters in patients with restless legs syndrome. Sleep 2004; 27: 907-914.
    CrossrefPubMedGoogle Scholar
  • 36 Hansen RA, Song L, Moore CG. et al. Effect of ropinirole on sleep outcomes in patients with restless legs syndrome: meta-analysis of pooled individual patient data from randomized controlled trials. Pharmacotherapy 2009; 29: 255-262.
    CrossrefPubMedGoogle Scholar
  • 37 Saletu B, Gruber G, Saletu M. et al. Sleep laboratory studies in restless legs syndrome patients as compared with normals and acute effects of ropinirole. 1. Findings on objective and subjective sleep and awakening quality. Neuropsychobiology 2000; 41: 181-189.
    PubMedGoogle Scholar
  • 38 Saletu M, Anderer P, Saletu B. et al. Sleep laboratory studies in restless legs syndrome patients as compared with normals and acute effects of ropinirole. 2. Findings on periodic leg movements, arousals and respiratory variables. Neuropsychobiology 2000; 41: 190-199.
    PubMedGoogle Scholar
  • 39 Trenkwalder C, Garcia-Borreguero D, Montagna P. et al. Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries. J Neurol Neurosurg Psychiatry 2004; 75: 92-97.
    PubMedGoogle Scholar
  • 40 Trenkwalder C. The weight of evidence for ropinirole in restless legs syndrome. Eur J Neurol 2006; 13 (Suppl. 03) 21-30.
    Google Scholar
  • 41 Benes H, Garcia-Borreguero D, Ferini-Strambi L. et al. Augmentation in the treatment of restless legs syndrome with transdermal rotigotine. Sleep Med 2012; 13: 589-597.
    CrossrefPubMedGoogle Scholar
  • 42 Garcia-Borreguero D, Oertel W, Trenkwalder C. Treatment of restless legs syndrome with rotigotine. Lancet Neurol 2011; 10: 872-873.
    CrossrefPubMedGoogle Scholar
  • 43 Hogl B, Oertel WH, Stiasny-Kolster K. et al. Treatment of moderate to severe restless legs syndrome: 2-year safety and efficacy of rotigotine transdermal patch. BMC Neurol 2010; 10: 86.
    CrossrefPubMedGoogle Scholar
  • 44 Inoue Y, Hirata K, Hayashida K. et al. Efficacy, safety and risk of augmentation of rotigotine for treating restless legs syndrome. Prog Neuropsychopharmacol Biol Psychiatry 2013; 40: 326-333.
    CrossrefPubMedGoogle Scholar
  • 45 Merlino G, Serafini A, Robiony F. et al. Restless legs syndrome: differential diagnosis and management with rotigotine. Neuropsychiatr Dis Treat 2009; 5: 67-80.
    PubMedGoogle Scholar
  • 46 Sixel-Doring F, Trenkwalder C. Rotigotine transdermal delivery for the treatment of restless legs syndrome. Expert Opin Pharmacother 2010; 11: 649-656.
    CrossrefPubMedGoogle Scholar
  • 47 Trenkwalder C, Benes H, Poewe W. et al. Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2008; 7: 595-604.
    CrossrefPubMedGoogle Scholar
  • 48 Stiasny K, Wetter TC, Winkelmann J. et al. Long-term effects of pergolide in the treatment of restless legs syndrome. Neurology 2001; 56: 1399-1402.
    CrossrefPubMedGoogle Scholar
  • 49 Trenkwalder C, Benes H, Grote L. et al. Cabergoline compared to levodopa in the treatment of patients with severe restless legs syndrome: results from a multi-center, randomized, active controlled trial. Mov Disord 2007; 22: 696-703.
    CrossrefPubMedGoogle Scholar
  • 50 Tintner R, Manian P, Gauthier P. et al. Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson Disease. Arch Neurol 2005; 62: 1290-1295.
    CrossrefPubMedGoogle Scholar
  • 51 Hirani N, Bayliff CC, McCormack DG. Diagnosis and management of pergolide-induced fibrosis. Mov Disord 2005; 20: 512-513 author reply 513.
    PubMedGoogle Scholar
  • 52 Mondal BK, Suri S. Pergolide-induced retroperitoneal fibrosis. Int J Clin Pract 2000; 54: 403.
    PubMedGoogle Scholar
  • 53 Walters AS, Wagner ML, Hening WA. et al. Successful treatment of the idiopathic restless legs syndrome in a randomized double-blind trial of oxycodone versus placebo. Sleep 1993; 16: 327-332.
    CrossrefPubMedGoogle Scholar
  • 54 Trenkwalder C, Benes H, Grote L. et al. Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a doubleblind, randomised, placebo-controlled trial with an openlabel extension. Lancet Neurol 2013; 12: 1141-1150.
    CrossrefPubMedGoogle Scholar
  • 55 Thorp ML, Morris CD, Bagby SP. A crossover study of gabapentin in treatment of restless legs syndrome among hemodialysis patients. Am J Kidney Dis 2001; 38: 104-108.
    CrossrefPubMedGoogle Scholar
  • 56 Allen RP. Pregabalin versus pramipexole for restless legs syndrome. N Engl J Med 2014; 370: 2050-2051.
    PubMedGoogle Scholar
  • 57 Joy MS. Clonazepam: benzodiazepine therapy for the restless legs syndrome. ANNA J 1997; 24: 686-689.
    PubMedGoogle Scholar
  • 58 Trotti LM, Bhadriraju S, Becker LA. Iron for restless legs syndrome. Cochrane Database Syst Rev 2012; 5: CD007834.
    PubMedGoogle Scholar
  • 59 Allen RP, Earley CJ. The role of iron in restless legs syndrome. Mov Disord 2007; 22 (Suppl. 18) S440-448.
    CrossrefPubMedGoogle Scholar
  • 60 Bartell S, Zallek S. Intravenous magnesium sulfate may relieve restless legs syndrome in pregnancy. J Clin Sleep Med 2006; 2: 187-188.
    PubMedGoogle Scholar
  • 61 Hornyak M, Voderholzer U, Hohagen F. et al. Magnesium therapy for periodic leg movements-related insomnia and restless legs syndrome: an open pilot study. Sleep 1998; 21: 501-505.
    CrossrefPubMedGoogle Scholar
  • 62 Hensley JG. Leg cramps and restless legs syndrome during pregnancy. J Midwifery Womens Health 2009; 54: 211-218.
    CrossrefPubMedGoogle Scholar
  • 63 Djokanovic N, Garcia-Bournissen F, Koren G. Medications for restless legs syndrome in pregnancy. J Obstet Gynaecol Can 2008; 30: 505-507.
    CrossrefPubMedGoogle Scholar
  • 64 Srivanitchapoom P, Pandey S, Hallett M. Restless legs syndrome and pregnancy: A review. Parkinsonism Relat Disord 2014; 20: 716-722.
    CrossrefPubMedGoogle Scholar
  • 65 Picchietti DL, Wang VC, Picchietti MA. Intravenous iron given prior to pregnancy for restless legs syndrome is associated with remission of symptoms. J Clin Sleep Med 2012; 8: 585-586.
    PubMedGoogle Scholar